サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1791749

非侵襲的ヘリコバクター・ピロリ検査の世界市場

Non-invasive Helicobacter Pylori Testing

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.90円
非侵襲的ヘリコバクター・ピロリ検査の世界市場
出版日: 2025年08月15日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

非侵襲的ヘリコバクター・ピロリ検査の世界市場は2030年までに4億4,590万米ドルに達する見込み

2024年に3億1,630万米ドルと推定される非侵襲的ヘリコバクター・ピロリ検査の世界市場は、2024～2030年の分析期間においてCAGR 5.9%で成長し、2030年には4億4,590万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである血清学的検査は、CAGR 6.3%を記録し、分析期間終了時には2億5,090万米ドルに達すると予測されます。尿素呼気試験セグメントの成長率は、分析期間中CAGR 4.8％と推定されます。

米国市場は8,320万米ドルと推定、中国はCAGR 5.8％で成長予測

米国の非侵襲的ヘリコバクター・ピロリ検査市場は2024年に8,320万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに7,180万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは5.8%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ5.5％と5.0％と予測されています。欧州では、ドイツがCAGR 4.7%で成長すると予測されています。

世界の非侵襲的ヘリコバクター・ピロリ検査市場- 主要動向と促進要因まとめ

なぜ非侵襲的検査がピロリ菌検出の優先ルートとして台頭しているのか？

世界の医療現場では、ヘリコバクター・ピロリ（ピロリ菌）の診断において、従来の侵襲的なアプローチに代わって非侵襲的な検査が急速に導入されるなど、大きな変化が起きています。歴史的には、生検を伴う内視鏡検査がこの胃病原体を同定するためのゴールド・スタンダードであったが、それはかなりの不快感、高いコスト、そして処置のリスクを伴うものであり、特に無症状の患者や小児患者にとってはそうでした。尿素呼気試験（UBT）、便中抗原試験（SAT）、血清学的検査などの非侵襲的検査は、その簡便性、迅速性、患者への優しさから、現在では臨床的にも商業的にも広く普及しています。これらの検査法では、鎮静剤を使用したり、侵襲的な方法で検体を採取したり、病院での処置を行うことなく、効率的に検出することができます。特に尿素呼気試験は、その精度の高さ、迅速性、初期診断と治療後の経過観察の両方に適している点で、際立っています。さらに、便中抗原検査は、その信頼性と検体採取の容易さから、特に小児科領域で広く採用されています。血清学的検査は、根絶後のモニタリングには限界があるもの、手ごろな価格で入手しやすいことが最も重要な低資源環境では、依然として広く使用されています。胃炎、潰瘍、胃がんに対する懸念の高まりに後押しされ、消化管の健康と早期検査に対する世界の意識の高まりが、こうした非侵襲的ソリューションの採用を大きく後押ししています。ヘルスケアプロバイダーが価値ベースのケアにシフトしている世界では、非侵襲的ピロリ菌診断は臨床効率と患者のコンプライアンスを強力に融合させ、消化器疾患管理の基準を再定義しています。

検査技術の進歩はどのように精度と患者の転帰を向上させているのか？

技術の進歩は、非侵襲的ピロリ菌診断の精度、アクセシビリティ、スケーラビリティを高める上で中心的な役割を果たしています。質量分析、イムノアッセイ、標識炭素同位体などの技術革新により、尿素呼気試験の感度と特異度が大幅に改善され、臨床医は極めて高い信頼性で活動性感染を検出できるようになりました。同様に、モノクローナル抗体ベースの便抗原検査の開発により、偽陰性を最小限に抑え、細菌量の少ないシナリオでも確実な結果が得られるようになり、診断精度が向上しました。近年では、サンプル調製、輸送媒体、在宅検査キットの進歩により、これらの診断法の適用範囲がさらに拡大し、地域社会や遠隔医療モデルに適したものとなっています。モバイル呼気検査ユニットやポータブル分析装置も市場に参入しており、地方の診療所、難民キャンプ、遠隔地の医療環境でのオンサイト診断が可能になっています。さらに、ラボベースの検査環境にAI主導の分析を統合することで、ワークフローを合理化し、迅速な結果解釈をサポートしており、これは特に高スループットの公衆衛生ラボで有用です。新興企業の中には、非同位体センサーを使った呼気バイオマーカー検出を模索しているところもあり、尿素呼気検査のコストと複雑さを軽減できる可能性があります。これらの技術革新を総称すると、診断の質を高めるだけでなく、より迅速な治療方針の決定、疾患進行リスクの低減、フォローアップレジメンに対する患者のアドヒアランスの向上が可能になります。迅速で正確なツールが病院の外で利用できるようになったことで、ピロリ菌検査は、利便性、迅速性、正確性といった現代のヘルスケアの期待に沿うものとなりつつあります。

公衆衛生の優先順位の変化とスクリーニングへの取り組みが市場の勢いを後押し？

公衆衛生の優先順位の変化と早期胃腸スクリーニングの重視の高まりは、非侵襲的ピロリ菌検査の採用増加の主な要因です。ピロリ菌は消化性潰瘍、慢性胃炎、胃がんなど、さまざまな胃疾患に関与しているため、特にアジア太平洋、ラテンアメリカ、東欧など有病率の高い地域では、早期発見と除菌が世界の保健戦略の焦点となっています。日本や韓国のような国々では、国家的な検診プログラムにより、非侵襲的検査が定期的な予防検診の一部としてすでに制度化されており、胃がん罹患率の測定可能な減少につながっています。欧米諸国では、未治療のピロリ菌感染と長期にわたる胃腸合併症との関連についての認識が高まり、顕在的な症状がない場合でも検診を勧めるように一般開業医を駆り立てています。COVID-19の大流行は、非侵襲的診断法への移行をさらに加速させました。ヘルスケアシステムは、クリニックでの処置を最小限に抑え、病院のインフラへの負担を軽減する方法を模索していたからです。非侵襲的検査は、このような改訂されたプロトコルにシームレスに適合し、在宅でのサンプル採取や非接触での診察をサポートします。さらに、医療保険会社や支払者は、非侵襲的な早期発見の費用対効果をますます認識するようになっており、呼気および便をベースとした検査への償還適用を拡大しつつあります。非政府組織や公衆衛生機関も、高負担で十分なサービスを受けていない地域における低コストの検査イニシアチブに資金を提供し、アクセスの公平性を強化しています。これらのプログラムが拡大し、成功が証明されるにつれて、非侵襲的ピロリ菌検査が予防的胃腸ケアの要であることの説得力が増しています。

非侵襲的ピロリ菌検査市場の拡大を促進する要因は何か？

非侵襲的ヘリコバクター・ピロリ検査市場の成長は、技術革新、ヘルスケア提供動向、患者の嗜好の変化、疾病負担の動態に関連するいくつかの要因によって牽引されています。技術レベルでは、診断プラットフォームの急速な進歩により、呼気および便をベースとした検査がより信頼性が高く効率的になり、臨床および家庭での幅広い使用に適しています。これらのプラットフォームはデジタルヘルスツールとますます統合され、結果の追跡、自動アラート、患者と医療提供者間のシームレスなコミュニケーションを可能にしています。臨床面では、外来診療と早期診断への嗜好の高まりが、リスクを最小限に抑え、ワークフローを合理化し、治療開始を早める非侵襲的方法を選択する医師の動機付けとなっています。エンドユーザーの需要も、腸の健康、食品由来病原体、未治療感染症の長期的リスクに対する消費者の意識の高まりに影響されています。患者、特に若年層やデジタル・ヘルス・リソースを利用できる患者は、侵襲性が低く、より簡便な検査オプションを積極的に求めています。これと並行して、劣悪な衛生環境、抗生物質耐性、食生活の変化などの要因によるピロリ菌の蔓延が進んでおり、先進国市場と新興国市場の両方において、拡張可能で費用対効果の高い診断薬に対するニーズが高まっています。コスト削減と予防医療指標の改善を迫られているヘルスケア・システムは、非侵襲的ソリューションを優先するスクリーニング・プログラムに投資しています。最後に、有利な規制状況や製薬会社の関与の拡大（特に除菌治療用の抗生物質を販売する製薬会社）が、診断薬を治療プロトコルにバンドルすることで検査の普及を促しています。これらの要因が重なり、非侵襲的ピロリ菌検査市場は世界規模で力強く持続的な成長を遂げています。

セグメント

検査タイプ（血清学的検査、尿素呼気検査、便/便中抗原検査）;検査方法（ラボベースの検査方法、Point of Care検査方法）;エンドユーザー（診断ラボエンドユーザー、病院エンドユーザー、クリニックエンドユーザー、その他エンドユーザー）

調査対象企業の例

  • Abbott Laboratories
  • Biohit Oyj
  • Biomerica, Inc.
  • Bio-Rad Laboratories, Inc.
  • Cardinal Health, Inc.
  • Certest Biotec S.L.
  • Coris Bioconcept SPRL
  • DiaSorin S.p.A.
  • Exalenz Bioscience Ltd.
  • Fujirebio Holdings, Inc.
  • Hoffmann-La Roche Ltd
  • Luminex Corporation
  • Meridian Bioscience, Inc.
  • Otsuka Holdings Co., Ltd.
  • QIAGEN N.V.
  • Quest Diagnostics Incorporated
  • Quidel Corporation
  • Sekisui Diagnostics, LLC
  • Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd.
  • Thermo Fisher Scientific Inc.

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP32372

Global Non-invasive Helicobacter Pylori Testing Market to Reach US$445.9 Million by 2030

The global market for Non-invasive Helicobacter Pylori Testing estimated at US$316.3 Million in the year 2024, is expected to reach US$445.9 Million by 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Serologic Test, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$250.9 Million by the end of the analysis period. Growth in the Urea Breath Test segment is estimated at 4.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$83.2 Million While China is Forecast to Grow at 5.8% CAGR

The Non-invasive Helicobacter Pylori Testing market in the U.S. is estimated at US$83.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$71.8 Million by the year 2030 trailing a CAGR of 5.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.5% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Global Non-Invasive Helicobacter Pylori Testing Market - Key Trends & Drivers Summarized

Why Is Non-Invasive Testing Emerging as the Preferred Route for Detecting H. Pylori?

The global healthcare landscape is witnessing a profound shift in the diagnosis of Helicobacter pylori (H. pylori) with non-invasive testing rapidly replacing traditional, invasive approaches. Historically, endoscopy with biopsy was the gold standard for identifying this gastric pathogen, but it came with considerable discomfort, higher costs, and procedural risks-especially for asymptomatic or pediatric patients. Non-invasive tests such as the urea breath test (UBT), stool antigen test (SAT), and serology are now gaining widespread clinical and commercial traction for their simplicity, speed, and patient-friendly nature. These methods allow for efficient detection without sedation, specimen collection through invasive means, or hospital-based procedures. The urea breath test, in particular, stands out due to its high accuracy, rapid turnaround time, and suitability for both initial diagnosis and post-treatment follow-up. Additionally, stool antigen tests have become widely adopted due to their reliability and ease of sample collection, especially in pediatric settings. Serological tests, while limited in post-eradication monitoring, are still widely used in low-resource settings where affordability and accessibility are paramount. The global increase in awareness of gastrointestinal health and early testing-fueled by growing concerns around gastritis, ulcers, and gastric cancers-is significantly propelling the adoption of these non-invasive solutions. In a world where healthcare providers are shifting toward value-based care, non-invasive H. pylori diagnostics offer a powerful blend of clinical efficiency and patient compliance, redefining standards in gastrointestinal disease management.

How Are Advancements in Testing Technology Enhancing Accuracy and Patient Outcomes?

Technological progress has played a central role in elevating the accuracy, accessibility, and scalability of non-invasive H. pylori diagnostics. Innovations in mass spectrometry, immunoassays, and labeled carbon isotopes have considerably improved the sensitivity and specificity of urea breath tests, allowing clinicians to detect active infections with exceptional confidence. Similarly, the development of monoclonal antibody-based stool antigen tests has enhanced diagnostic precision by minimizing false negatives and providing robust results even in low bacterial load scenarios. In recent years, advancements in sample preparation, transport media, and at-home testing kits have further expanded the reach of these diagnostics, making them more suitable for community and telehealth models. Mobile breath testing units and portable analyzers are also entering the market, enabling on-site diagnosis in rural clinics, refugee camps, and remote health settings. Furthermore, the integration of AI-driven analytics in lab-based testing environments is streamlining workflow and supporting quicker result interpretation, which is especially useful in high-throughput public health labs. Some emerging companies are even exploring breath biomarker detection using non-isotopic sensors, potentially reducing the cost and complexity of urea breath testing. Collectively, these innovations are not only raising the bar for diagnostic quality but also enabling faster treatment decisions, lowering disease progression risks, and improving patient adherence to follow-up regimens. With rapid and accurate tools now available outside of hospital walls, H. pylori testing is becoming more aligned with modern healthcare expectations-convenience, speed, and precision.

Are Shifting Public Health Priorities and Screening Initiatives Boosting Market Momentum?

Changing public health priorities and the growing emphasis on early gastrointestinal screening are key contributors to the increasing adoption of non-invasive H. pylori testing. With the bacterium implicated in a wide array of gastric disorders-including peptic ulcers, chronic gastritis, and gastric cancer-early detection and eradication have become focal points in global health strategies, especially in regions with high prevalence rates such as Asia-Pacific, Latin America, and Eastern Europe. National screening programs in countries like Japan and South Korea have already institutionalized non-invasive testing as part of routine preventive health check-ups, leading to measurable reductions in gastric cancer incidence. In Western countries, increased awareness about the link between untreated H. pylori infection and long-term gastrointestinal complications has spurred general practitioners to recommend screening even in the absence of overt symptoms. The COVID-19 pandemic has further accelerated the shift toward non-invasive diagnostics, as healthcare systems sought ways to minimize in-clinic procedures and reduce the burden on hospital infrastructure. Non-invasive tests fit seamlessly into these revised protocols, supporting home-based sample collection and contactless consultations. Additionally, health insurers and payers are increasingly recognizing the cost-effectiveness of early, non-invasive detection, and are extending reimbursement coverage to breath and stool-based tests. Non-governmental organizations and public health agencies are also funding low-cost testing initiatives in high-burden, underserved areas, reinforcing equity in access. As these programs expand and prove successful, the case for non-invasive H. pylori testing as a cornerstone of preventive gastrointestinal care becomes increasingly compelling.

What Factors Are Driving the Expansion of the Non-Invasive H. Pylori Testing Market?

The growth in the non-invasive Helicobacter pylori testing market is driven by several factors linked to technological innovation, healthcare delivery trends, changing patient preferences, and disease burden dynamics. At the technological level, rapid advancements in diagnostic platforms have led to more reliable and efficient breath and stool-based tests, making them suitable for widespread clinical and at-home use. These platforms are increasingly integrated with digital health tools, enabling result tracking, automated alerts, and seamless communication between patients and providers. On the clinical front, a growing preference for outpatient care and early diagnosis is motivating physicians to opt for non-invasive methods that minimize risk, streamline workflows, and accelerate treatment initiation. End-user demand is also being influenced by rising consumer awareness around gut health, foodborne pathogens, and the long-term risks of untreated infections. Patients, particularly in younger age groups and those with access to digital health resources, are actively seeking less invasive, more convenient testing options. In parallel, the increasing prevalence of H. pylori-driven by factors such as poor sanitation, antibiotic resistance, and changing dietary patterns-is fueling the need for scalable, cost-effective diagnostics across both developed and emerging markets. Healthcare systems under pressure to reduce costs and improve preventive care metrics are investing in screening programs that prioritize non-invasive solutions. Lastly, favorable regulatory landscapes and greater involvement from pharmaceutical companies-particularly those marketing antibiotics for eradication therapy-are encouraging widespread testing by bundling diagnostics with treatment protocols. These converging factors are ensuring strong, sustained growth in the non-invasive H. pylori testing market on a global scale.

SCOPE OF STUDY:

The report analyzes the Non-invasive Helicobacter Pylori Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Test Type (Serologic Test, Urea Breath Test, Stool / Fecal Antigen Test); Method (Laboratory-based Test Method, Point of Care Test Method); End-Use (Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -

  • Abbott Laboratories
  • Biohit Oyj
  • Biomerica, Inc.
  • Bio-Rad Laboratories, Inc.
  • Cardinal Health, Inc.
  • Certest Biotec S.L.
  • Coris Bioconcept SPRL
  • DiaSorin S.p.A.
  • Exalenz Bioscience Ltd.
  • Fujirebio Holdings, Inc.
  • Hoffmann-La Roche Ltd
  • Luminex Corporation
  • Meridian Bioscience, Inc.
  • Otsuka Holdings Co., Ltd.
  • QIAGEN N.V.
  • Quest Diagnostics Incorporated
  • Quidel Corporation
  • Sekisui Diagnostics, LLC
  • Shenzhen Zhonghe Headway Bio-Sci & Tech Co., Ltd.
  • Thermo Fisher Scientific Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Non-invasive Helicobacter Pylori Testing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Preference for Patient-Friendly Diagnostics Throws the Spotlight on Non-Invasive H. Pylori Testing Methods
    • Global Emphasis on Early Detection of Gastric Disorders Strengthens the Business Case for Non-Invasive Testing
    • Surge in Dyspepsia and Gastric Ulcer Cases Propels Growth Across Primary and Secondary Care Settings
    • Advancements in Urea Breath and Stool Antigen Tests Drive Accuracy and Broaden Clinical Adoption
    • Wider Integration into Preventive Health Check-Ups Expands the Addressable Market Opportunity
    • Government Screening Programs and Public Health Campaigns Accelerate Demand in High-Prevalence Regions
    • Shift Toward Decentralized and At-Home Testing Solutions Drives Adoption Among Convenience-Seeking Patients
    • Rise in Pediatric and Geriatric Gastrointestinal Care Spurs Demand for Gentler, Non-Invasive Test Options
    • Increased Awareness of H. Pylori's Role in Gastric Cancer Sustains Growth in Diagnostic Uptake
    • Healthcare Digitization and Lab Automation Strengthen Throughput and Efficiency of Non-Invasive Testing
    • Improved Sample Collection and Transport Technologies Drive Expansion in Remote and Low-Infrastructure Areas
    • Decline in Preference for Endoscopic Testing Creates Opportunities for Rapid, Low-Risk Alternatives
    • Pharmaceutical Alignment with Diagnostic Pathways Spurs Test-and-Treat Strategies Using Non-Invasive Methods
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Non-invasive Helicobacter Pylori Testing Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Serologic Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Serologic Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Urea Breath Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Urea Breath Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Stool / Fecal Antigen Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Stool / Fecal Antigen Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Laboratory-based Test Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Laboratory-based Test Method by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Point of Care Test Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Point of Care Test Method by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Non-invasive Helicobacter Pylori Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 22: USA Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • CANADA
    • TABLE 28: Canada Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Canada 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • JAPAN
    • Non-invasive Helicobacter Pylori Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 34: Japan Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Japan 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • CHINA
    • Non-invasive Helicobacter Pylori Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 40: China Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: China 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 42: China Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • EUROPE
    • Non-invasive Helicobacter Pylori Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 46: Europe Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 47: Europe 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • FRANCE
    • Non-invasive Helicobacter Pylori Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 54: France Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: France 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 58: France Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • GERMANY
    • Non-invasive Helicobacter Pylori Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 60: Germany Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Germany 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • ITALY
    • TABLE 66: Italy Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Italy 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 70: Italy Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • UNITED KINGDOM
    • Non-invasive Helicobacter Pylori Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 72: UK Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: UK 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 76: UK Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Rest of Europe 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Non-invasive Helicobacter Pylori Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Asia-Pacific 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 90: Rest of World Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Test Type - Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of World 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Test Type - Percentage Breakdown of Value Sales for Serologic Test, Urea Breath Test and Stool / Fecal Antigen Test for the Years 2025 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by Method - Laboratory-based Test Method and Point of Care Test Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by Method - Percentage Breakdown of Value Sales for Laboratory-based Test Method and Point of Care Test Method for the Years 2025 & 2030
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Non-invasive Helicobacter Pylori Testing by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for Non-invasive Helicobacter Pylori Testing by End-Use - Percentage Breakdown of Value Sales for Diagnostic Laboratories End-Use, Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2025 & 2030

IV. COMPETITION